Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Wilms Tumor 3Rhabdomyosarcoma, Embryonal 3Rhabdomyosarcoma 3Rhabdomyosarcoma, Alveolar 2Stage I Mixed Cell Type Kidney Wilms Tumor 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Pleuropulmonary blastoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Beckwith-Wiedemann Syndrome 1

Interventions

Doxorubicin 3pembrolizumab 2pazopanib 2Ifosfamide 2toripalimab 1selinexor 1peposertib 1liposomal doxorubicin 1anlotinib 1Specimen Handling 1Radiotherapy 1Radiation 1Proton Therapy 1Magnetic Resonance Spectroscopy 1Histamine H2 Antagonists 1Famotidine 1Dactinomycin 1Biopsy 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dermatofibrosarcoma × Dactinomycin × 90 days × Clear all
NCT04332874 2026-04-23

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
30 enrolled
Sarcoma

Sarcoma, Dermatofibrosarcoma, Sarcoma, Alveolar Soft Part, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡